Zemcelpro® Positive Results in High- and Very High-Risk Blood Cancers to be Reported at the EBMT 2026 Annual Meeting

Zemcelpro® (dorocubicel) achieved remarkable and clinically meaningful survival results in patients with high- and very high-risk acute leukemias and myelodysplastic syndromesView original content:https://www.prnewswire.co.uk/news-releases/zemcelpro-dorocubicel-positive-results-in-high--and-very-high-risk-blood-cancers-to-be-reported-at-the-ebmt-2026-annual-meeting-302708650.html

en | boerse | 68906142 |